OakChart

Haleon plc ADR

HLNHealthcare·Drug Manufacturers - Specialty & Generic·United Kingdom·Large·NYSE·Nov 11 • 3:59 PM ET

9.10+0.04 (0.44%)
2026-11-12 03:34 CET
Market cap
39,998.14 USD m
Revenue, TTM
14,967.67 USD m
Net income, TTM
2,177.99 USD m
Free cash flow, TTM
2,750.67 USD m
EPS diluted, TTM
0.49
P/E
18.71
Compare

Price

HLN against its 20, 50 and 200-day averages
2050200earnings
8.509.009.5010.0010.5028.4M56.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HLNclose 9.1020-day 9.5450-day 9.37200-day 9.729.1052w low

19.3% under the 52-week high of 11.28 on 18 Feb 2026. 52-week low 8.38 on 29 Oct 2026. Last 15 sessions, 24.0% high to low

Volume 1.20× normal · the line is the 50-bar volume average

Profile

HLN
52-week range, 25% of the way up
8.3811.28

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

IPOJul 18, 2022
Beta0.13
ATR, 14d0.26
Rel volume1.20
Short float0.33%
Insider own0.00%
Inst own14.09%

Snapshot

6 groups

Valuation

Index-
Market Cap40.00B
Enterprise Value49.93B
Income2.18B
Sales14.97B
Book/sh4.96
Cash/sh0.25
Dividend Est.0.22 (2.36%)
Dividend TTM0.20 (2.18%)
Dividend Ex-DateAug 14, 2026
Dividend Gr. 3/5Y44.22% -
Payout37.42%
Employees-
IPOJul 18, 2022

Ratios

P/E18.71
Forward P/E15.32
PEG1.96
P/S2.67
P/B1.84
P/C36.48
P/FCF14.54
EV/EBITDA12.61
EV/Sales3.34
Quick Ratio0.52
Current Ratio0.69
Debt/Eq0.50
LT Debt/Eq0.38
Option/ShortYes / Yes

Earnings

EPS (ttm)0.49
EPS next Y0.59
EPS next Q0.15
EPS this Y9.64%
EPS next Y6.44%
EPS next 5Y7.82%
EPS past 3/5Y20.04% 9.00%
Sales past 3/5Y2.82% 2.76%
EPS Y/Y TTM12.37%
Sales Y/Y TTM4.99%
EPS Q/Q24561.95%
Sales Q/Q15.22%
EarningsJul 30 BMO
EPS/Sales Surpr.3.63% 1.18%

Ownership

Insider Own0.00%
Insider Trans-
Inst Own14.09%
Inst Trans-0.14%
ROA5.02%
ROE9.99%
ROIC7.24%
Gross Margin65.46%
Oper. Margin23.31%
Profit Margin14.55%
SMA20-4.61%
SMA50-2.86%
SMA200-6.37%
Trades-

Technical

Shs Outstand4.40B
Shs Float4.39B
Short Float0.33%
Short Ratio0.82
Short Interest14.59M
52W High11.28 -19.33%
52W Low8.38 8.59%
Volatility2.17% 1.96%
ATR (14)0.26
RSI (14)44.44
Beta0.13
Rel Volume1.20
Avg Volume17.80M
Volume21,451,777

Performance

Perf Week-1.41%
Perf Month-3.60%
Perf Quarter-7.14%
Perf Half Y0.89%
Perf YTD-9.99%
Perf Year-7.61%
Perf 3Y12.48%
Perf 5Y-
Perf 10Y-
Recom2.11
Target Price10.21
Prev Close9.06
Price9.10
Change %0.44%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 04, 2026DowngradeJJefferiesBuy → Hold
Oct 30, 2026UpgradeDDeutsche BankSell → Hold
Jan 23, 2026UpgradeBBarclaysEqual Weight → Overweight
Sep 16, 2025DowngradeBBarclaysOverweight → Equal Weight
Sep 10, 2025UpgradeGGoldmanNeutral → Buy
May 27, 2025UpgradeBBNP Paribas ExaneNeutral → Outperform$13.40+47.3%
May 09, 2025UpgradeMMorgan StanleyEqual-Weight → Overweight$11.25+23.6%
Mar 05, 2025DowngradeHHSBC SecuritiesBuy → Hold
Jan 10, 2025DowngradeMMorgan StanleyOverweight → Equal-Weight
Jan 08, 2025DowngradeBBernsteinOutperform → Mkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
KVUEKenvue Inc37.09B
PRGOPerrigo Company plc2.30B
PBHPrestige Consumer Healthcare Inc2.09B
CLColgate-Palmolive Co77.90B
CHDChurch & Dwight Co Inc26.44B
PGProcter & Gamble Co388.62B
GSKGSK Plc ADR101.43B
ULUnilever plc ADR141.71B
JNJJohnson & Johnson675.03B
KMBKimberly-Clark Corp66.80B

Held by

AUM
TickerCompanyAUM
PPHVanEck Pharmaceutical ETFAUM: 1.09B
AVDEAvantis International Equity ETFAUM: 19.73B
AQECAQE Core ETFAUM: 604.49M
YLDEFranklin ClearBridge Enhanced Income ETFAUM: 180.81M
QLTIGMO International Quality ETFAUM: 289.87M
GKATScharf Global Opportunity ETFAUM: 169.58M
LOEVHarding Loevner Intl Dev SelectAUM: 87.93M
APIEActivePassive International Equity ETFAUM: 1.13B
VUSVVanguard Wellington U.S. Value Active ETFAUM: 93.37M
DIVSGuinness Atkinson Dividend Builder ETFAUM: 36.87M

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-07-300.2770.2670.2287,5227,4343
2025S22026-02-250.2600.2510.2577,5127,5712
2025S12025-07-310.2440.2450.2317,2527,4792
2024S22025-02-270.2270.2160.2027,1436,9142
2024S12024-08-010.2300.2280.2007,2847,3052
2024Q12024-05-010.1150.1120.1153,6473,6972
2023Q42024-02-290.1030.118-0.0543,5003,4572
2023Q32023-11-020.1080.1120.0483,4063,4802
2023S12023-08-020.2160.2190.1837,2797,0642
2023Q12023-05-030.1050.1310.1023,7423,5921
2022Q42023-03-020.1140.1220.0503,3213,2912
2022Q32022-11-100.112-0.0883,378-2
2022Q22022-09-200.080-0.0473,0813,081-
2024Q3--0.120--3,6972
2024Q4--0.109--3,5681
2026S2--0.279--7,5802

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY0.4400.4540.28312,98013,154
2023FY0.4380.4460.28214,29614,252
2024FY0.4520.4380.40214,18513,946
2025FY0.5090.4990.50114,92914,903
2026FY-0.558--15,127
2027FY-0.594--15,630
2028FY-0.638--16,234
2029FY-0.677--16,744
2030FY-0.740--17,439

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026S2S2026-10-281017,5807,5807,580
2026S2S2026-10-061017,6857,6857,685
2026S2S2026-09-221007,7247,7247,724
2026S2S2026-07-301007,7907,7907,790
2026S2S2026-06-291017,7807,7807,780
2026S2S2026-04-291007,8677,8677,867
2026S2S2026-03-251017,7947,7947,794
2026S2S2026-02-251007,8917,8917,891
2026S2E2026-10-292010.280.280.28
2026S2E2026-10-281010.280.280.28
2026S2E2026-10-061010.280.280.28
2026S2E2026-09-221000.290.290.29
2026S2E2026-09-121000.290.290.29
2026S2E2026-09-051100.290.290.29

Estimate history

EPS, annual0.1810.3180.4140.2830.2820.4020.487
Period2019202020212022202320242025
EPS, quarterly0.102
PeriodQ1 '23
Sales, annual10818.26712685.05213127.27513374.66914048.97214353.66614536.33
Period2019202020212022202320242025
Sales, quarterly3628.128
PeriodQ1 '23
Shares, annual4617.2874617.2874617.2874617.2874617.2874526.384452.654
Period2019202020212022202320242025
Shares, quarterly-
PeriodQ1 '23

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue14,967.6714,536.3314,353.6714,048.9713,374.6713,127.2812,685.0510,818.27
Cost of Goods Sold Incl. D&A5,169.775,163.495,355.315,460.735,142.684,944.225,106.344,692.17
Gross Profit9,797.909,372.848,998.358,588.258,231.998,183.067,578.726,126.10
Selling, General and Administrative Excl. Other6,309.475,967.415,793.605,474.405,235.075,497.095,256.373,917.79
Research and Development416.01415.14379.51369.19373.23353.45389.84372.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income3,488.443,405.433,204.753,113.842,996.922,685.972,322.342,208.30
Interest Expense425.42477.08516.24528.30347.3619.2525.6528.07
Unusual Expense311.70185.82451.07689.89453.30400.21773.261,012.94
Net Income Before Taxes2,862.712,836.102,440.622,023.691,993.022,250.002,040.231,130.30
Income Taxes665.93622.04555.85642.66614.66270.93525.77253.87
Consolidated Net Income2,196.782,214.061,884.771,381.031,378.361,979.061,514.46876.43
Net Income From Continuing Operations2,177.992,196.921,842.611,303.961,305.691,911.671,468.30835.61
Net Income2,177.992,196.921,842.611,303.961,305.691,911.671,468.30835.61
EPS (Recurring)0.540.520.470.390.350.470.440.33
EPS (Basic, Before Extraordinaries)0.490.490.400.280.280.410.320.18
EPS (Diluted)0.490.490.400.280.280.410.320.18
EBITDA3,960.823,879.873,618.763,497.953,350.443,054.552,713.462,540.00
Non-Operating Income (Expense)111.4093.57203.17128.03-203.24-16.50516.79-37.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense97.6693.90112.1382.0481.6765.7365.4459.93
Price To Earnings Ratio18.6218.6231.9725.5919.4919.49--
Price To Sales Ratio2.783.143.052.712.76---
Gross Margin65.4664.4862.6961.1361.5562.3459.7556.63
Operating Margin23.3123.4322.3322.1622.4120.4618.3120.41
Net Margin14.5515.1112.849.289.7614.5611.587.72
Shares Outstanding4,386.934,452.654,526.384,617.294,617.294,617.294,617.294,617.29
Market Capitalization39,998.1439,998.1443,184.5338,000.3036,938.3236,938.32--

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue7,535.607,432.077,105.887,149.777,201.686,972.887,075.966,659.92
Cost of Goods Sold Incl. D&A2,558.502,611.272,522.072,671.972,605.453,000.192,693.262,706.25
Gross Profit4,977.104,820.804,583.814,477.804,596.223,972.694,382.713,953.66
Selling, General and Administrative Excl. Other3,179.973,129.503,005.742,914.642,955.802,696.922,849.872,898.88
Research and Development197.74218.28197.10198.78180.86195.50173.88192.63
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income1,797.141,691.301,578.081,563.161,640.421,275.771,532.841,054.78
Interest Expense205.81219.61228.22246.54244.10229.34270.07210.25
Unusual Expense227.3384.3633.71320.12196.04186.73119.620.00
Net Income Before Taxes1,420.491,442.221,393.951,179.801,259.72837.151,183.85885.64
Income Taxes384.72281.21339.73249.13306.08359.67283.63210.25
Consolidated Net Income1,035.781,161.011,054.21930.67953.65477.47900.22675.39
Net Income From Continuing Operations1,025.011,152.971,045.14924.22918.23453.66847.19637.80
Net Income1,025.011,152.971,045.14924.22918.23453.66847.19637.80
EPS (Recurring)0.270.270.240.250.230.130.200.14
EPS (Basic, Before Extraordinaries)0.230.260.230.200.200.100.180.14
EPS (Diluted)0.230.260.230.200.200.100.180.14
EBITDA2,023.131,937.691,806.291,783.891,833.941,472.531,720.281,236.84
Non-Operating Income (Expense)56.5054.9077.80183.2959.44-22.5640.6941.11
Stock Option Compensation Expense53.4744.1940.8565.8346.48---
Price To Earnings Ratio18.6223.2525.7031.9729.3225.5926.0619.49
Price To Sales Ratio2.783.133.303.042.682.712.832.76
Gross Margin66.0564.8664.5162.6363.8256.9761.9459.37
Operating Margin23.8522.7622.2121.8622.7818.3021.6615.84
Net Margin13.6015.5114.7112.9312.756.5111.979.58
Shares Outstanding4,386.934,452.654,478.784,526.384,566.154,617.294,617.294,617.29
Market Capitalization39,998.1445,019.2246,627.9843,184.5337,716.4038,000.3038,692.8936,938.32

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments1,780.852,817.901,330.89822.78560.74456.56450.42
Short Term Receivables2,855.542,690.162,482.042,378.135,256.624,990.735,329.47
Inventories1,378.681,490.361,794.921,621.511,288.081,297.241,604.27
Other Current Assets104.91162.81534.1460.156.77101.15313.97
Total Current Assets6,119.987,161.226,141.994,882.577,112.226,845.697,698.12
Net Property, Plant & Equipment2,686.062,405.862,424.672,284.312,251.102,189.852,147.42
Total Investments and Advances102.22102.7082.8652.9316.250.000.00
Long-Term Note Receivable49.77------
Intangible Assets34,450.7732,826.6634,234.7534,205.6636,834.2737,205.6537,108.90
Deferred Tax Assets388.72345.66337.82264.64422.59343.10336.49
Other Assets91.46134.01191.22188.8625.7369.7117.22
Total Assets43,888.9842,976.1143,413.3141,878.9646,662.1646,654.0047,308.15
Short Term Debt Incl. Current Port. of LT Debt1,124.461,862.32836.27525.671,224.42522.17690.19
Accounts Payable2,768.112,470.992,364.752,207.321,854.241,831.711,591.02
Income Tax Payable359.13294.31367.14252.61273.60322.60259.65
Other Current Liabilities2,383.432,651.332,346.912,271.082,387.902,810.453,114.49
Total Current Liabilities6,635.137,278.955,915.075,256.675,740.165,486.945,655.36
Long Term Debt10,455.0710,820.7411,218.2412,032.61117.84143.53160.29
Provision for Risks Charges207.14235.45249.86224.94379.25548.15495.46
Deferred Tax Liabilities4,333.754,199.304,445.234,331.644,546.894,610.724,655.17
Other Liabilities86.08122.74258.78236.9712.1919.1427.82
Total Liabilities21,717.1822,657.1722,087.1822,082.8410,796.3210,808.4710,994.10
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00
Common Equity22,092.4520,246.3021,169.3319,644.5635,696.5335,693.8036,193.49
Total Shareholders Equity22,092.4520,246.3021,169.3319,644.5635,696.5335,693.8036,193.49
Accumulated Minority Interest79.3672.64156.80151.57169.31151.73120.55
Total Equity22,171.8020,318.9421,326.1319,796.1335,865.8435,845.5336,314.05
Total Liabilities & Stockholders Equity43,888.9842,976.1143,413.3141,878.9646,662.1646,654.0047,308.15
Book Value Per Share4.964.474.584.257.737.737.84
Tangible Book Value Per Share-2.78-2.78-2.83-3.15-0.25-0.33-0.20
Price to Book Ratio1.842.081.821.131.13--
Return on Assets5.064.273.062.954.103.13-
Return on Equity10.388.906.394.725.364.08-
Return on Invested Capital6.755.934.034.125.344.102.30
Quick Ratio0.710.780.730.621.011.011.08
Current Ratio0.920.981.040.931.241.251.36

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income2,231.272,214.061,884.771,381.031,378.361,979.061,514.46876.43
Depreciation479.85474.44414.01384.10353.52368.58391.12331.69
Other Funds (Non Cash)347.54105.43159.73537.00332.58-115.5360.27399.31
Funds from Operations3,006.432,742.532,312.842,274.782,140.832,075.331,785.041,584.47
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital198.92337.38263.23-133.01222.95-209.0519.24-588.12
Cash from Operating Activities3,205.353,079.912,576.072,141.782,363.791,866.291,804.27996.35
Capital Expenditures-574.10-544.29-406.34-417.67-404.02-409.84-407.79-310.00
Net Assets From Acquisitions-7.38-229.31-623.57-88.260.00---
Sale of Fixed Assets and Businesses32.8817.13569.900.000.00154.03519.35497.54
Purchase or Sale of Investments0.04-7.910.000.00-11,345.930.000.000.00
Purchase of Investments-8.03-7.910.000.00-11,345.930.000.000.00
Sale Or Maturity of Investments8.070.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources28.250.00415.29305.79906.59188.421,184.90153.09
Cash from Investing Activities-520.31-764.38-44.72-200.13-10,843.36-67.391,296.46340.62
Cash Dividends Paid-867.90-806.55-728.35-482.30-3,303.63-1,578.85-3,040.46-1,469.65
Change in Capital Stock-1,008.15-861.90-797.35-47.240.000.000.000.00
Repurchase of Common Pref Stock-1,008.15-861.90-797.35-47.240.000.000.000.00
Sale of Common Pref Stock0.000.000.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-2,303.09-1,721.16833.13-687.4111,684.7011.0035.911.28
Change in Long Term Debt0.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow56.7526.36-111.17-161.60388.01-59.14-39.75378.89
Other Financing Activities Uses0.44-14.50-111.17-161.60-59.13-64.64-39.75-48.48
Cash from Financing Activities-2,508.25-3,442.33-880.41-1,446.918,713.61-1,679.25-3,100.73-1,143.06
Exchange Rate Effect-7.16-64.58-100.95-18.6518.48-6.88-7.69-17.86
Net Change in Cash169.63-1,191.371,549.99476.09252.51112.77-7.69176.05
Free Cash Flow2,750.672,655.552,256.621,850.901,989.321,552.721,519.59753.96
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Price to Free Cash Flow22.1024.6828.6427.85----
Deferred Taxes & Investment Tax Credit--51.40-145.67-27.3576.37-156.78-180.81-22.96

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments1,096.311,780.85926.362,817.90671.241,330.89
Short Term Receivables3,116.382,855.543,024.362,690.162,803.772,482.04
Inventories1,421.481,378.681,548.501,490.361,848.111,794.92
Other Current Assets61.05104.91179.52162.81630.79534.14
Total Current Assets5,695.236,119.985,678.737,161.225,953.916,141.99
Net Property, Plant & Equipment2,732.812,686.062,561.182,405.862,353.752,424.67
Total Investments and Advances102.20102.22106.89102.70109.9882.86
Intangible Assets34,170.0534,450.7734,758.9332,826.6633,329.2634,234.75
Deferred Tax Assets378.27388.72360.40345.66333.72337.82
Other Assets164.5891.46149.37134.01135.26191.22
Total Assets43,243.1343,888.9843,615.5042,976.1142,215.8843,413.31
Short Term Debt Incl. Current Port. of LT Debt2,604.061,124.461,114.091,862.321,834.21836.27
Accounts Payable5,038.245,017.044,881.194,640.144,549.504,494.94
Income Tax Payable351.72359.13316.55294.31389.34367.14
Other Current Liabilities293.32134.50216.52482.17336.25216.72
Total Current Liabilities8,287.356,635.136,528.357,278.957,109.305,915.07
Long Term Debt8,348.4010,455.0710,505.1010,820.749,363.1911,218.24
Deferred Tax Liabilities4,365.334,333.754,390.604,199.304,224.624,445.23
Other Liabilities195.1186.0852.07122.74149.16258.78
Total Liabilities21,423.1421,717.1821,692.6422,657.1721,096.5622,087.18
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity21,740.3522,092.4521,844.7520,246.3020,984.0621,169.33
Total Shareholders Equity21,740.3522,092.4521,844.7520,246.3020,984.0621,169.33
Accumulated Minority Interest79.6479.3678.1172.64135.26156.80
Total Equity21,819.9922,171.8021,922.8620,318.9421,119.3221,326.13
Total Liabilities & Stockholders Equity43,243.1343,888.9843,615.5042,976.1142,215.8843,413.31
Book Value Per Share4.964.964.884.474.604.58
Tangible Book Value Per Share-2.83-2.78-2.88-2.78-2.70-2.83
Price to Book Ratio1.842.072.322.081.801.82
Return on Assets5.025.064.594.273.203.05
Return on Equity9.9910.389.208.906.556.37
Return on Invested Capital3.413.543.232.973.031.40
Quick Ratio0.520.710.630.780.580.73
Current Ratio0.690.920.870.980.841.04

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income1,035.781,195.491,054.21950.29953.65492.10
Depreciation225.99253.86228.22224.71193.51199.80
Other Funds (Non Cash)266.3481.2025.93172.73-11.38529.06
Funds from Operations1,528.111,478.331,308.361,200.581,135.781,193.39
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-322.84521.76-178.94574.51-308.61293.82
Cash from Operating Activities1,205.272,000.081,129.421,775.09827.171,487.21
Capital Expenditures-188.32-385.78-167.27-268.82-141.66-243.50
Net Assets From Acquisitions0.00-7.38-225.62-629.910.00-1.42
Sale of Fixed Assets and Businesses33.63-0.7518.15575.700.000.00
Purchase or Sale of Investments8.07-8.030.000.000.000.00
Purchase of Investments0.00-8.030.000.000.000.00
Sale Or Maturity of Investments8.070.000.000.000.000.00
Other Uses0.000.000.0012.65-12.650.00
Other Sources28.250.000.000.87418.64294.73
Cash from Investing Activities-118.37-401.94-374.74-309.52264.3449.80
Cash Dividends Paid-586.49-281.41-538.13-245.02-490.74-212.48
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-614.74-393.41-482.37-404.53-400.94-47.62
Repurchase of Common Pref Stock-614.74-393.41-482.37-404.53-400.94-47.62
Sale of Common Pref Stock0.000.000.000.000.000.00
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-554.21-47.62-1,701.261,541.03-699.43-583.27
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow4.0452.72-25.93-18.71-93.59-12.47
Other Financing Activities Uses-10.7611.20-25.93-18.71-93.59-12.47
Cash from Financing Activities-1,795.79-712.46-2,785.30833.27-1,722.64-893.95
Exchange Rate Effect39.01-46.17-19.45-98.18-3.7921.90
Net Change in Cash-669.89839.52-2,050.072,200.67-634.92664.96
Free Cash Flow1,057.301,693.371,004.941,561.16718.401,344.40
Price to Free Cash Flow22.1024.1926.3628.2627.9627.62

Revenue breakdown

Digestive Health2024: 1.31B 2025: 1.30B
Oral Health2024: 4.23B 2025: 4.56B
Pain Relief2024: 3.28B 2025: 3.38B
Respiratory Health2024: 2.71B 2025: 2.47B
Therapeutic Skin Health and Other2024: 651.74M 2025: 606.07M
Vitamins, Minerals And Supplements2024: 2.17B 2025: 2.22B
China2024: 1.26B
Rest of World2024: 7.98B
United Kingdom2024: 490.73M 2025: 14.53B
United States2024: 4.62B
Asia Pacific2024: 3.27B 2025: 3.39B
EMEA And Latin America2024: 5.92B 2025: 6.05B
North America2024: 5.17B 2025: 5.09B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.33%14.6M4395.4M15.87M
2026-10-150.42%18.5M4397.6M14.55M
2026-09-300.56%24.8M4397.6M12.83M
2026-09-150.50%21.8M4397.6M10.40M
2026-08-310.35%15.4M4397.6M9.63M
2026-08-140.30%13.3M4397.6M9.50M
2026-07-310.41%18.1M4403.9M10.20M
2026-07-150.29%12.6M4403.8M8.88M
2026-06-300.32%14.1M4403.8M8.99M
2026-06-150.34%15.0M4414.4M8.65M
2026-05-290.26%11.7M4423.0M8.38M
2026-05-150.34%14.9M4429.2M8.87M
2026-04-300.34%15.3M4438.5M8.24M
2026-04-150.28%12.4M4453.0M8.39M
2026-03-310.43%19.3M4458.6M8.75M
2026-03-130.37%16.5M4452.7M8.57M
2026-02-270.38%17.0M4453.9M9.03M
2026-02-130.42%18.6M4453.0M8.84M
2026-01-300.40%17.8M4453.0M9.13M
2026-01-150.45%19.9M4453.0M9.30M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.506.306.706.605.5392.004.000.974-0.0250.001
call5.003.804.404.103.7793.006.000.947-0.0230.002
call7.501.451.851.511.60292.000.000.881-0.0180.003
call10.000.000.050.050.5351,5570.000.136-0.0090.003
call12.500.000.150.051.2831910.000.068-0.0130.002
call15.000.000.750.101.8151.000.000.051-0.0150.001
call17.500.000.050.002.1310.000.000.044-0.0150.001
call20.000.000.750.302.5821.000.000.039-0.0170.001
put2.500.000.750.005.3870.000.00-0.025-0.0250.001
put5.000.000.750.002.7210.000.00-0.052-0.0230.002
put7.500.000.100.051.1291050.00-0.118-0.0180.003
put10.000.651.351.101.38781.000.00-0.863-0.0090.003
put12.502.904.003.502.7500.000.00-0.932-0.0130.002
put15.005.306.705.303.9130.000.00-0.948-0.0140.001
put17.507.809.208.024.5040.000.00-0.956-0.0150.001
put20.0010.2011.7010.204.9830.000.00-0.960-0.0160.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-11-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-02SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-29SEC
2026-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-01SEC
2026-09-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-24SEC
2026-09-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-18SEC
2026-09-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-01SEC
2026-08-26CERTSEC
2026-08-218-A12BSEC
2026-08-216-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-21SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-19SEC
2026-08-176-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-17SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-08-13424B5SEC
2026-08-13FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-11SEC
2026-08-11424B5SEC
2026-08-11POSASRPost-effective amendment to an automatic shelf registration statement of Form S-3ASR or Form F-3ASRSEC
2026-08-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-03SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-29SEC
2026-07-306-K/A2026-06-30SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-29F-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersSEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-02SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
DODGE & COX3.40%
FMR LLC2.90%
Clearbridge Investments, LLC0.73%
MORGAN STANLEY0.44%
Mondrian Investment Partners LTD0.40%
Nuveen, LLC0.38%
HARRIS ASSOCIATES L P0.38%
HARDING LOEVNER LP0.35%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP0.32%
BANK OF AMERICA CORP /DE/0.25%

Funds

Fund% owned
Dodge & Cox International Stock Fund3.51%
Dodge & Cox Stock Fund2.43%
ClearBridge Dividend Strategy Fund1.03%
Dodge & Cox Global Stock Fund0.69%
EUPAC Fund0.60%
Fidelity Series Large Cap Stock Fund0.43%
Strategic Advisers Fidelity U.S. Total Stock Fund0.33%
Oakmark International Fund0.30%
Fidelity Growth and Income Portfolio0.27%
Dodge & Cox Balanced Fund0.26%

OakChart. HLN. Cached 15 minutes.

Some panels did not load: insider.